Johnson & Johnson's nipocalimab meets primary endpoint in lupus trial

June 3, 2026 12:04 AM

Johnson & Johnson (NYSE: JNJ) announced that its experimental drug nipocalimab met the primary endpoint in a Phase 2 study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found